Table 1.

Seroprevalence of Viral Hepatitis Infections in Rural Bangladesh at 3 Time Points, 2003–2005

Enzyme Immunoassay	December 2003–April 2004 Baseline Seroprevalence		December 2004–April 2005 12-Month Follow-up Seroprevalence		June 2005–November 2005 18-Month Follow-up Seroprevalence
	No. Positive/ No. Tested	%	No. Positive/ No. Tested	%	No. Positive/ No. Tested	%
Anti-HEV (total immunoglobulin)a	255/1,134	22.5	270/1,025	26.3	247/1,011	24.4
Anti-HBc (total immunoglobulin)b	380/1,080	35.2	369/960	38.4	357/1,011	35.3
Anti-HCV (IgG)b	14/917	1.5	—c		—c
Anti-HAV (total immunoglobulin)b	116/124	93.5	—d		—d

Abbreviations: anti-HAV, antibody to hepatitis A virus; anti-HBc, antibody to hepatitis B core antigen; anti-HCV, antibody to hepatitis C virus; anti-HEV, antibody to hepatitis E virus; IgG, immunoglobulin G; WR-U, Walter Reed antibody units.

^a“Positive” defined as ≥20 WR-U/mL, with no significant differences between groups by Fisher's exact test.

^bAbbott commercial assay (Abbott Laboratories, Abbott Park, Illinois), with no significant differences between groups by Fisher's exact test.

^c—, not tested because of limited serum volumes and low baseline seroprevalence.

^d—, only tested for less than 10 years because of limited serum volumes and high baseline seroprevalence.